View Future GrowthAbbVie 과거 순이익 실적과거 기준 점검 0/6AbbVie 의 수입은 연평균 -21%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 15.6%의 비율로 증가했습니다. 매출은 연평균 2%의 비율로 증가해 왔습니다.핵심 정보-20.99%순이익 성장률-21.03%주당순이익(EPS) 성장률Biotechs 산업 성장률36.30%매출 성장률2.00%자기자본이익률n/a순이익률5.72%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트AbbVie Inc. to Report Q1, 2026 Results on Apr 29, 2026Mar 31AbbVie Inc. to Report Q4, 2025 Results on Feb 04, 2026Jan 07AbbVie Inc. Announces Intangible Asset Impairment for the Third Quarter Ended September 30, 2025Nov 01AbbVie Inc. to Report Q3, 2025 Results on Oct 31, 2025Oct 02AbbVie Inc. to Report Q2, 2025 Results on Jul 31, 2025Jun 30+ 8 more updatesAbbVie Inc. to Report Q1, 2025 Results on Apr 25, 2025Mar 31모든 업데이트 보기Recent updatesAbbVie Announces Superiority of Rinvoq Versus Humira for Primary Endpoint in Head-To-Head Study in Rheumatoid Arthritis PatientsApr 29+ 2 more updatesAbbvie Provides Update on Trenibotulinumtoxine Biologics License Application in the U.SApr 24AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (Elahere) in Platinum-Sensitive Ovarian CancerApr 13+ 1 more updateAbbVie Inc. to Report Q1, 2026 Results on Apr 29, 2026Mar 31AbbVie Announces to Present New Research Across its Dermatology Portfolio at 2026 American Academy of Dermatology Annual MeetingMar 27AbbVie Inc., Annual General Meeting, May 08, 2026Mar 10+ 1 more updateAbbVie Announces Positive Topline Results from Phase 3 Affirm Study Evaluating SKYRIZI®? (Risankizumab) Subcutaneous Induction in Patients with Crohn's DiseaseMar 03U.S. Food and Drug Administration Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)Feb 20+ 1 more updateAbbVie Inc. Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVO) in Adults and Adolescents With VitiligoFeb 03AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaJan 17AbbVie Denies Media Reports of Talks to Buy Revolution MedicinesJan 08+ 1 more updateAbbVie Inc. to Report Q4, 2025 Results on Feb 04, 2026Jan 07Abbvie Receives Health Canada Approval for the Treatment of Acute Hepatitis C VirusJan 06AbbVie to Feature New Data At ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood CancersDec 02+ 1 more updateAbbVie Corporation Announces Two Positive Updates for Canadians Living with Ulcerative ColitisNov 28AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular LymphomaNov 19Abbvie Announces New 6-Month 45Mg Luprolide Acetate for Extended-Release Injectable SuspensionNov 18AbbVie Inc. Announces Launch of Second WindsNov 15AbbVie Inc. Announces Intangible Asset Impairment for the Third Quarter Ended September 30, 2025Nov 01AbbVie Inc. Declares Increase in Quarterly Cash Dividend, Payable on February 17, 2026Oct 31AbbVie Corporation Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian CancersOct 30Abbvie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (Rinvoq®?) in Adult and Adolescents with VitiligoOct 29Abbvie Announces Positive Topline Results from the Phase 3B/4 Head-To-Head StudyOct 21AbbVie Announces U.S. Food and Drug Administration Approves Updated Indication Statement for RINVOQ®? (upadacitinib) for the Treatment of Inflammatory Bowel DiseaseOct 14Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid TumorsOct 13AbbVie Announces Positive Topline Results from Phase 2 Elite Trial Evaluating OnabotulinumtoxinA (BotoX®?) for the Treatment of Upper Limb Essential TremorOct 07AbbVie Inc. to Report Q3, 2025 Results on Oct 31, 2025Oct 02AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab Sunirine (PVEK) - an Investigational Antibody-Drug Conjugate to Treat Rare Cancer with Limited Treatment OptionsOct 01AbbVie Announces UK Pricing Strategy for ELAHERE®? (Mirvetuximab Soravtansine-gynx)Sep 30+ 1 more updateAbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's DiseaseSep 26+ 1 more updateAbbVie's VRAYLAR®? (Cariprazine) Now Publicly Reimbursed in AlbertaSep 16Abbvie Inc. Declares Quarterly Dividend, Payable on November 14, 2025Sep 05AbbVie Announces Updated Results from Phase 2 EPCORE®? NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients with Relapsed/Refractory (R) Diffuse Large B-Cell Lymphoma (DLBCL)Sep 03+ 1 more updateAbbvie Announces Positive Topline Results from Second Phase 3 Up-Aa Trial Evaluating Upadacitinib (Rinvoq®?) for Alopecia AreataAug 21AbbVie Inc. (NYSE:ABBV) completed the acquisition of Capstan Therapeutics, Inc.Aug 19AbbVie Reportedly in Talks to Acquire Gilgamesh in $1 Billion DealJul 31Abbvie Announces Positive Topline Results from Phase 3 Up-Aa Trial Evaluating Upadacitinib for Alopecia AreataJul 30Abbvie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic LeukemiaJul 29AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in CanadaJul 13AbbVie Inc. to Report Q2, 2025 Results on Jul 31, 2025Jun 30+ 8 more updatesAbbVie Inc Declares Quarterly Cash Dividend, Payable August 15, 2025Jun 20Genentech and AbbVie Provide Update on Phase III Verona StudyJun 18+ 2 more updatesU.S. FDA Approves Expanded Indication for Abbvie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C VirusJun 12Abbvie Features New Data Across Difficult-To-Treat Solid Tumors and Blood Cancers At Asco 2025May 27The Gross Law Firm Files Lawsuit Against Cerevel Therapeutics Holdings, IncMay 22Abbvie Announces U.S. FDA Approves Emrelis for Adults with Previously Treated Advanced Non-Small Cell Lung Cancer (Nsclc) with High C-Met Protein OverexpressionMay 15AbbVie Inc. Announces U.S. Food and Drug Administration Approval for Giant Cell ArteritisApr 29AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar LinesApr 25AbbVie Inc. Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell ArteritisApr 08AbbVie Inc. to Report Q1, 2025 Results on Apr 25, 2025Mar 31AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025Mar 26AbbVie Announces Final Analysis of the Confirmatory Phase 3 MIRASOL Trial Evaluating the Efficacy and Safety of ELAHERE®?Mar 16AbbVie Inc., Annual General Meeting, May 09, 2025Mar 11AbbVie Announces SKYRIZI (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel DiseaseMar 05AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®?) for the Treatment of Adults with Giant Cell ArteritisFeb 28AbbVie Inc. Announces Board Changes, Effective July 1, 2025Feb 14+ 1 more updateAbbvie Announces the U.S. Food and Drug Administration Approves Emblaveo™Feb 08AbbVie Inc. (NYSE:ABBV) completed the acquisition of Nimble Therapeutics, Inc.Jan 24Abbvie and Regenxbio Inc. Announce Updates on the Abbv-Rgx-314 Clinical ProgramJan 13AbbVie Inc. to Report Q4, 2024 Results on Jan 31, 2025Jan 03AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million.Dec 13AbbVie Inc. (NYSE:ABBV) complete the acquisition of Aliada Therapeutics, Inc. from Johnson & Johnson Innovation - JJDC, Inc., RA Capital Management, L.P., RA Ventures, OrbiMed Advisors LLC and Sanofi Ventures.Dec 11Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell LymphomaDec 10+ 1 more updateAbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational EpcoritamabDec 09Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian CancerNov 19AbbVie Provides Update on Phase 2 Results for Emraclidine in SchizophreniaNov 12AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025Nov 02AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.Oct 28U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's DiseaseOct 17Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple HollowingOct 03AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024Oct 01Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung CancerSep 28Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma ManagementSep 18AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of SchizophreniaSep 05Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaAug 20AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access ProcessAug 15AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.Aug 02AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisJul 26매출 및 비용 세부 내역AbbVie가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BASE:ABBV 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2662,8193,59513,9299,47331 Dec 2561,1604,18613,6449,06830 Sep 2559,6442,34812,6018,78730 Jun 2558,3283,72313,2158,56831 Mar 2557,3674,15513,3468,38531 Dec 2456,3344,23814,0998,13130 Sep 2455,5335,08113,9687,75530 Jun 2455,0005,29813,1937,40531 Mar 2454,4035,95113,0327,18931 Dec 2354,3184,82012,4197,03830 Sep 2355,1386,47112,4536,89730 Jun 2356,0238,63512,2606,78531 Mar 2356,7417,53512,2016,66131 Dec 2258,05411,78214,5846,48730 Sep 2257,81913,34312,1166,51830 Jun 2257,34912,56911,9886,55131 Mar 2256,72512,40711,9436,69231 Dec 2156,19711,46811,8726,82030 Sep 2155,1697,46511,0546,82930 Jun 2153,7296,59910,8606,76131 Mar 2150,1955,09210,9556,41831 Dec 2045,8044,5569,8676,00330 Sep 2040,6507,3249,4295,90230 Jun 2036,2276,9068,2885,58231 Mar 2034,0578,3956,7605,46731 Dec 1933,2667,8426,7635,37730 Sep 1932,8673,2326,4875,26030 Jun 1932,6244,0936,7655,27331 Mar 1932,6475,3336,8735,30431 Dec 1832,7535,6577,3535,25930 Sep 1832,1877,5316,9725,24230 Jun 1830,9466,4196,6235,20231 Mar 1829,6126,3526,3035,10931 Dec 1728,2165,2836,2485,00730 Sep 1727,2736,6155,9584,78930 Jun 1726,7106,5825,7994,66731 Mar 1726,2186,2785,8614,56231 Dec 1625,6385,9235,8374,38530 Sep 1625,2426,0485,7334,17830 Jun 1624,7545,6905,7244,47231 Mar 1623,7775,4485,6464,23631 Dec 1522,8595,1185,6634,10130 Sep 1521,9112,7906,0593,97830 Jun 1520,9862,0646,1783,390양질의 수익: ABBV는 $13.6B 규모의 큰 일회성 손실이 있어 31st March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: ABBV의 현재 순 이익률 (5.7%)은 지난해 (7.2%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ABBV의 수익은 지난 5년 동안 연평균 21% 감소했습니다.성장 가속화: ABBV은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: ABBV은 지난 1년 동안 수익이 감소(-13.5%)하여 Biotechs 업계 평균(11.7%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: ABBV의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/02 20:39종가2026/04/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AbbVie Inc.는 51명의 분석가가 다루고 있습니다. 이 중 27명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David ToungArgus Research CompanyEmily FieldBarclaysLuisa HectorBerenberg48명의 분석가 더 보기
AbbVie Inc. Announces Intangible Asset Impairment for the Third Quarter Ended September 30, 2025Nov 01
AbbVie Announces Superiority of Rinvoq Versus Humira for Primary Endpoint in Head-To-Head Study in Rheumatoid Arthritis PatientsApr 29+ 2 more updates
AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (Elahere) in Platinum-Sensitive Ovarian CancerApr 13+ 1 more update
AbbVie Announces to Present New Research Across its Dermatology Portfolio at 2026 American Academy of Dermatology Annual MeetingMar 27
AbbVie Announces Positive Topline Results from Phase 3 Affirm Study Evaluating SKYRIZI®? (Risankizumab) Subcutaneous Induction in Patients with Crohn's DiseaseMar 03
U.S. Food and Drug Administration Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)Feb 20+ 1 more update
AbbVie Inc. Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVO) in Adults and Adolescents With VitiligoFeb 03
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaJan 17
AbbVie to Feature New Data At ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood CancersDec 02+ 1 more update
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular LymphomaNov 19
AbbVie Inc. Announces Intangible Asset Impairment for the Third Quarter Ended September 30, 2025Nov 01
AbbVie Corporation Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian CancersOct 30
Abbvie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (Rinvoq®?) in Adult and Adolescents with VitiligoOct 29
AbbVie Announces U.S. Food and Drug Administration Approves Updated Indication Statement for RINVOQ®? (upadacitinib) for the Treatment of Inflammatory Bowel DiseaseOct 14
Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid TumorsOct 13
AbbVie Announces Positive Topline Results from Phase 2 Elite Trial Evaluating OnabotulinumtoxinA (BotoX®?) for the Treatment of Upper Limb Essential TremorOct 07
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab Sunirine (PVEK) - an Investigational Antibody-Drug Conjugate to Treat Rare Cancer with Limited Treatment OptionsOct 01
AbbVie Announces UK Pricing Strategy for ELAHERE®? (Mirvetuximab Soravtansine-gynx)Sep 30+ 1 more update
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's DiseaseSep 26+ 1 more update
AbbVie Announces Updated Results from Phase 2 EPCORE®? NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients with Relapsed/Refractory (R) Diffuse Large B-Cell Lymphoma (DLBCL)Sep 03+ 1 more update
Abbvie Announces Positive Topline Results from Second Phase 3 Up-Aa Trial Evaluating Upadacitinib (Rinvoq®?) for Alopecia AreataAug 21
Abbvie Announces Positive Topline Results from Phase 3 Up-Aa Trial Evaluating Upadacitinib for Alopecia AreataJul 30
Abbvie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic LeukemiaJul 29
U.S. FDA Approves Expanded Indication for Abbvie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C VirusJun 12
Abbvie Announces U.S. FDA Approves Emrelis for Adults with Previously Treated Advanced Non-Small Cell Lung Cancer (Nsclc) with High C-Met Protein OverexpressionMay 15
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar LinesApr 25
AbbVie Inc. Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell ArteritisApr 08
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025Mar 26
AbbVie Announces Final Analysis of the Confirmatory Phase 3 MIRASOL Trial Evaluating the Efficacy and Safety of ELAHERE®?Mar 16
AbbVie Announces SKYRIZI (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel DiseaseMar 05
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®?) for the Treatment of Adults with Giant Cell ArteritisFeb 28
AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million.Dec 13
AbbVie Inc. (NYSE:ABBV) complete the acquisition of Aliada Therapeutics, Inc. from Johnson & Johnson Innovation - JJDC, Inc., RA Capital Management, L.P., RA Ventures, OrbiMed Advisors LLC and Sanofi Ventures.Dec 11
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell LymphomaDec 10+ 1 more update
AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational EpcoritamabDec 09
Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian CancerNov 19
AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.Oct 28
U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's DiseaseOct 17
Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple HollowingOct 03
Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung CancerSep 28
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma ManagementSep 18
AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of SchizophreniaSep 05
Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaAug 20
AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access ProcessAug 15
AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.Aug 02
AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisJul 26